Patents by Inventor Scott S. Harried

Scott S. Harried has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20240002349
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: June 20, 2023
    Publication date: January 4, 2024
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 11834418
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 5, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Kv7 channel activators compositions and methods of use
    Patent number: 11724990
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: August 15, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20230000831
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: January 7, 2022
    Publication date: January 5, 2023
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • KV7 channel activators compositions and methods of use
    Patent number: 11261162
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: March 1, 2022
    Assignee: KNOPP BIOSCIENCES, LLC
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20210188782
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, James S. HALE, Scott S. HARRIED, Charles A. FLENTGE, David A. MARESKA
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20210130299
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 6, 2021
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 10906877
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: February 2, 2021
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Kv7 channel activators compositions and methods of use
    Patent number: 10851067
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: December 1, 2020
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • Control of surface properties by deposition of particle monolayers
    Patent number: 10797189
    Abstract: The physical and chemical properties of surfaces can be controlled by bonding nanoparticles, microspheres, or nanotextures to the surface via inorganic precursors. Surfaces can acquire a variety of desirable properties such as antireflection or reflection, antifogging, antifrosting, UV blocking, and IR absorption, while maintaining transparency to visible light. Micro or nanomaterials can also be used as etching masks to texture a surface and control its physical and chemical properties via its micro or nanotexture.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: October 6, 2020
    Assignee: NANOCLEAR TECHNOLOGIES INC.
    Inventors: Harold Frank Greer, Scott S. Harried, Ryan Morrow Briggs, Tony Lee
  • CONTROL OF SURFACE PROPERTIES BY DEPOSITION OF PARTICLE MONOLAYERS
    Publication number: 20200066927
    Abstract: The physical and chemical properties of surfaces can be controlled by bonding nanoparticles, microspheres, or nanotextures to the surface via inorganic precursors. Surfaces can acquire a variety of desirable properties such as antireflection or reflection, antifogging, antifrosting, UV blocking, and IR absorption, while maintaining transparency to visible light. Micro or nanomaterials can also be used as etching masks to texture a surface and control its physical and chemical properties via its micro or nanotexture.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 27, 2020
    Inventors: Harold Frank GREER, Scott S. HARRIED, Ryan Morrow BRIGGS, Tony LEE
  • CONTROL OF LIGHT SCATTERING WITH NANOPARTICLES AND/OR COATINGS
    Publication number: 20200025981
    Abstract: The optical scattering response of a textured substrate is altered by the addition of one or more layers of nanoparticles and/or coatings. The nanoparticles and/or coatings have a refractive index that is comparable, or higher, than the refractive index of the substrate. The scattering cross section of the substrate is reduced by partially or completely filling gaps in the substrate. A material having a hazy appearance to visible light is therefore rendered more transparent by the addition of nanoparticles.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 23, 2020
    Inventors: Harold Frank GREER, Ryan Morrow BRIGGS, Sihan SHEN, Scott S. HARRIED, Tony LEE, Raymond LOBATON, Vahid MIRKHANI
  • Imidazo[4,5-b]pyridin-2-yl amides as Kv7 channel activators
    Patent number: 10526328
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 7, 2020
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Charles A. Flentge, James S. Hale, David A. Mareska, Justin K. Belardi, Kai Zhang, Scott S. Harried
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20200002292
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 2, 2020
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, James S. HALE, Scott S. HARRIED, Charles A. FLENTGE, David A. MARESKA
  • Control of surface properties by deposition of particle monolayers
    Patent number: 10510911
    Abstract: The physical and chemical properties of surfaces can be controlled by bonding nanoparticles, microspheres, or nanotextures to the surface via inorganic precursors. Surfaces can acquire a variety of desirable properties such as antireflection or reflection, antifogging, antifrosting, UV blocking, and IR absorption, while maintaining transparency to visible light. Micro or nanomaterials can also be used as etching masks to texture a surface and control its physical and chemical properties via its micro or nanotexture.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: December 17, 2019
    Assignee: NANOCLEAR TECHNOLOGIES INC.
    Inventors: Harold Frank Greer, Scott S. Harried, Ryan Morrow Briggs, Tony Lee
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20190284142
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 19, 2019
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 10385025
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 20, 2019
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • CONTROL OF SURFACE PROPERTIES BY DEPOSITION OF PARTICLE MONOLAYERS
    Publication number: 20190074389
    Abstract: The physical and chemical properties of surfaces can be controlled by bonding nanoparticles, microspheres, or nanotextures to the surface via inorganic precursors. Surfaces can acquire a variety of desirable properties such as antireflection or reflection, antifogging, antifrosting, UV blocking, and IR absorption, while maintaining transparency to visible light. Micro or nanomaterials can also be used as etching masks to texture a surface and control its physical and chemical properties via its micro or nanotexture.
    Type: Application
    Filed: October 3, 2018
    Publication date: March 7, 2019
    Inventors: Harold Frank GREER, Scott S. HARRIED, Ryan Morrow BRIGGS, Tony LEE
  • IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
    Publication number: 20190002464
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Application
    Filed: September 7, 2018
    Publication date: January 3, 2019
    Inventors: Lynn RESNICK, George T. TOPALOV, Charles A. FLENTGE, James S. HALE, David A. MARESKA, Justin K. BELARDI, Kai ZHANG, Scott S. HARRIED
  • Control of surface properties by deposition of particle monolayers
    Patent number: 10121919
    Abstract: The physical and chemical properties of surfaces can be controlled by bonding nanoparticles, microspheres, or nanotextures to the surface via inorganic precursors. Surfaces can acquire a variety of desirable properties such as antireflection or reflection, antifogging, antifrosting, UV blocking, and IR absorption, while maintaining transparency to visible light. Micro or nanomaterials can also be used as etching masks to texture a surface and control its physical and chemical properties via its micro or nanotexture.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: November 6, 2018
    Assignee: NANOCLEAR TECHNOLOGIES INC.
    Inventors: Harold Frank Greer, Scott S. Harried, Ryan Morrow Briggs, Tony Lee